Cellectis says the U.S. patent issued to the company this month will facilitate the development of future development of future T-cell immunotherapy treatments based on CRISPR-Cas . . .

Get GEN Edge Today!

The post Cellectis’ New Patent Supports CRISPR-Based T-Cell Immunotherapies appeared first on GEN – Genetic Engineering and Biotechnology News.

Source